EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers

Yan Gao, Xing Zhou, Chengmeng Liu, Qianhui Zhou

Frontiers in Immunology · 17.11.2026 · 17

DOI: 10.3389/fimmu.2026.1998406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 17.11.2026. Verfasst von Yan Gao und 3 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant chemoimmunotherapy has made the resection specimen a central response readout in resectable non-small-cell lung cancer (NSCLC). Residual viable tumor percentage quantifies treatment effect but does not describe how malignant, immune, stromal, and vascular compartments are organized within the post-treatment tumor bed. Here, we critically review spatial and single-cell studies of treatment-remodeled NSCLC and distinguish direct post-treatment evidence from pretreatment, immunotherapy-only, untreated, and cross-cancer evidence. Recurring but not yet validated observations include mature tertiary lymphoid structures, coordinated B- and T-cell programs, T-cell access to tumor, and selected antigen-presenting myeloid states. Candidate resistance mechanisms include interferon-responsive fibroblast programs, extracellular-matrix barriers, context-dependent myeloid states, and malignant-cell plasticity. Pretreatment BAG3-positive fibroblast neighborhoods provide a related hypothesis whose post-treatment persistence remains unproven. However, cell abundance alone is insufficient, tertiary lymphoid structure density is not consistently associated with pathological complete response, and most proposed spatial metrics lack definitions prespecified and fixed before validation or independent validation. We propose pathology-anchored multiregion sampling, patient-level spatial analysis, explicit handling of tumor-centered metrics that are undefined in tumor-free compartments, and staged assay simplification. This Review provides a pathology-anchored framework for evaluating spatial immune–stromal features as candidate residual-disease biomarkers. Their incremental value beyond pathological burden and circulating tumor DNA requires external validation before biomarker-guided treatment can be tested.

Zitieren

APA

Gao, Y., Zhou, X., Liu, C., & Zhou, Q. (2026). Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1998406

Vancouver

Gao Y, Zhou X, Liu C, Zhou Q. Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1998406

BibTeX
@article{Gao2026,
  author = {Gao, Yan and Zhou, Xing and Liu, Chengmeng and Zhou, Qianhui},
  title = {Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1998406}
}
Kostenlos starten →